La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GenMont Biotech Incorporation Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

We Think That There Are More Issues For GenMont Biotech Incorporation (TWSE:3164) Than Just Sluggish Earnings

Mar 19

Should You Or Shouldn't You: A Dividend Analysis on GenMont Biotech Incorporation (TPE:3164)

Apr 04

GenMont Biotech Incorporation's(TPE:3164) Share Price Is Down 26% Over The Past Five Years.

Feb 14

Is GenMont Biotech Incorporation's (TPE:3164) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 24

Tread With Caution Around GenMont Biotech Incorporation's (TPE:3164) 3.5% Dividend Yield

Jan 03

Are GenMont Biotech Incorporation's (TPE:3164) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 08

AMMINISTRATORE DELEGATO

GenMont Biotech Incorporation non ha un CEO, o non abbiamo dati su di loro.

GenMont Biotech Incorporation Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

GenMont Biotech Incorporation, Annual General Meeting, May 29, 2024

GenMont Biotech Incorporation, Annual General Meeting, May 28, 2021

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.17 (vs NT$0.033 in 2Q 2023)

GenMont Biotech Incorporation to Report Q2, 2024 Results on Aug 05, 2024

Dividend reduced to NT$0.50

Genmont Biotech Incorporation Announces the 2023 Cash Dividend, Payable on July 10, 2024

First quarter 2024 earnings released: EPS: NT$0.40 (vs NT$0.095 in 1Q 2023)

GenMont Biotech Incorporation to Report Q1, 2024 Results on May 07, 2024

We Think That There Are More Issues For GenMont Biotech Incorporation (TWSE:3164) Than Just Sluggish Earnings

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: NT$0.38 (vs NT$0.66 in FY 2022)

GenMont Biotech Incorporation, Annual General Meeting, May 29, 2024

New minor risk - Earnings quality

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.03 (vs NT$0.14 in 2Q 2022)

Upcoming dividend of NT$0.70 per share at 2.7% yield

Full year 2022 earnings released: EPS: NT$0.66 (vs NT$1.31 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.09 (vs NT$0.27 in 3Q 2021)

Second quarter 2022 earnings released: EPS: NT$0.14 (vs NT$0.17 in 2Q 2021)

Upcoming dividend of NT$1.10 per share

First quarter 2022 earnings released: EPS: NT$0.27 (vs NT$0.35 in 1Q 2021)

Third quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.33 in 3Q 2020)

Upcoming dividend of NT$0.70 per share

Second quarter 2021 earnings released: EPS NT$0.17 (vs NT$0.17 in 2Q 2020)

Investor sentiment improved over the past week

Should You Or Shouldn't You: A Dividend Analysis on GenMont Biotech Incorporation (TPE:3164)

Full year 2020 earnings released: EPS NT$0.69 (vs NT$0.65 in FY 2019)

GenMont Biotech Incorporation, Annual General Meeting, May 28, 2021

New 90-day high: NT$24.80

GenMont Biotech Incorporation's(TPE:3164) Share Price Is Down 26% Over The Past Five Years.

New 90-day low: NT$20.55

Is GenMont Biotech Incorporation's (TPE:3164) Recent Price Movement Underpinned By Its Weak Fundamentals?

New 90-day low: NT$22.00

Tread With Caution Around GenMont Biotech Incorporation's (TPE:3164) 3.5% Dividend Yield

New 90-day low: NT$22.35

Are GenMont Biotech Incorporation's (TPE:3164) Statutory Earnings A Good Guide To Its Underlying Profitability?

Third quarter 2020 earnings released: EPS NT$0.33

First half earnings released

Upcoming Dividend of NT$0.81 Per Share

New 90-day low - NT$23.30

AMMINISTRATORE DELEGATO